Impact of Dapagliflozin on Gut Microbiota and Plasma Metabolomic Profiles in Patients With Heart Failure
Dapagliflozin modulates gut microbiota composition and circulating metabolic signatures in HF patients, supporting a potential gut-heart axis mechanism contributing to its cardioprotective effects.
Authors
- Wenjing Zhu (ORCID: https://orcid.org/0009-0008-4764-3261)
- Ying Zhang (ORCID: https://orcid.org/0009-0001-4204-359X)
- Yan Liu (ORCID: https://orcid.org/0000-0003-2649-2552)
- Zhong Fang (ORCID: https://orcid.org/0009-0008-5012-6409)
- Chao Ma (ORCID: https://orcid.org/0009-0007-0570-6351)
- Zhen Zhu (ORCID: https://orcid.org/0009-0001-9896-2034)
- Qingling Zhang (ORCID: https://orcid.org/0009-0008-3723-398X)
- Xiaodong Xu (ORCID: https://orcid.org/0009-0002-9493-2281)
- Qinpei Liu (ORCID: https://orcid.org/0009-0007-7385-8584)
Institutions
- Chizhou University (CN)
- Key Laboratory of Guangdong Province (CN)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2025-11-27
- DOI
- https://doi.org/10.31083/fbl46142
- Citations
- 1
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Hainan University